Journal of Vaccine Research 2024, Vol.14, No.6, 287-296 http://medscipublisher.com/index.php/jvr 295 Jiang F., 2024, Investigation on the differentiation and functions of immunological memory cells, Journal of Vaccine Research, 14(1): 31-38. https://doi.org/10.5376/jvr.2024.14.0005 Lalwani S., Chatterjee S., Balasubramanian S., Bavdekar A., Mehta S., Datta S., Povey M., and Henry O., 2015, Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial, BMJ Open, 5: e007202. https://doi.org/10.1136/bmjopen-2014-007202 PMid: 25968041 La Torre G., Saulle R., Unim B., Meggiolaro A., Barbato A., Mannocci A., and Spadea A., 2017, The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: a retrospective cohort study, Human Vaccines & Immunotherapeutics, 13: 1879-1883. https://doi.org/10.1080/21645515.2017.1330733 Marin M., Broder K., Temte J., Snider D., and Seward J., 2010, Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recommendations and Reports, 59(RR-3): 1-12. McLean H., Fiebelkorn A., Ogee-Nwankwo A., Hao L., Coleman L., Adebayo A., and Icenogle J., 2018, Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults, Vaccine, 36(38): 5732-5737. https://doi.org/10.1016/j.vaccine.2018.08.010 Nakayama T., Eda M., Hirano M., and Goto W., 2019, Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial, Human Vaccines & Immunotherapeutics, 15: 1139-1144. https://doi.org/10.1080/21645515.2019.1578591 Pebody R., Gay N., Hesketh L., Vyse A., Morgan‐Capner P., Brown D., Litton P., and Miller E., 2002, Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance, Vaccine, 20(7-8): 1134-1140. https://doi.org/10.1016/S0264-410X(01)00435-2 PMid: 11858860 Platt H., Tochihara S., Oda Y., and Ueda K., 2021, Immunogenicity and safety of KM-248, a combined measles, mumps, and rubella vaccine, and the noninferiority to a measles vaccine in healthy Japanese children: phase 3 randomized multicenter single-blind clinical trial, Japanese Journal of Infectious Diseases, Online ahead of print. https://doi.org/10.7883/yoken.JJID.2020.876 PMid: 34210818 Povey M., Henry O., Bergsaker M., Chlibek R., Esposito S., Flodmark C., Gothefors L., Man S., Silfverdal S., Štefkovičová M., Usonis V., Wysocki J., Gillard P., and Prymula R., 2019, Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial, The Lancet Infectious Diseases, 19(3): 287-297. https://doi.org/10.1016/S1473-3099(18)30716-3 Prymula R., Povey M., Brzostek J., Cabrnochová H., Chlibek R., Czajka H., Levinienė G., Man S., Neamtu M., Pazdiora P., Pleșca D., Růžková R., Štefkovičová M., Usonis V., Verdanova D., Wysocki J., Casabona G., and Habib M., 2021, Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: results from five East European countries, Vaccine, 39(20): 2872-2880. https://doi.org/10.1016/j.vaccine.2021.03.085 Rojo C., Iglesias R., Olvera J., and Girón Á., 2003, Study of the immune response engendered by different combined measles, mumps and rubella (MMR) vaccines in an area of Andalusia (Spain), Vaccine, 22(2): 280-286. https://doi.org/10.5376/ijmms.2024.14.0005 Santos E., Noronha T., Alves I., De Souza Cruz R., De Vasconcellos Ferroco C., Brum R., Oliveira P., Siqueira M., Lima M., Ramos F., Bragagnolo C., Camacho L., and Maia M., 2019, Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study, Memórias do Instituto Oswaldo Cruz, 114. https://doi.org/10.1590/0074-02760180517 Tischer A., and Gerike E., 2000, Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella, Vaccine, 18(14): 1382-1392. https://doi.org/10.1016/S0264-410X(99)00397-7 Wang W., 2024, Studying the dynamic changes of the immune system through single-cell omics, International Journal of Molecular Medical Science, 14(1): 29-41. https://doi.org/10.5376/ijmms.2024.14.0005 White C., Stinson D., Staehle B., Cho I., Matthews H., Ngai A., Keller P., Eiden J., and Kuter D., 1997, Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children, Clinical Infectious Diseases, 24(5): 925-931. https://doi.org/10.1093/clinids/24.5.925 Yhu-Chering H., Jo D., Kim C., Kim H., Kim K., Kim K., Kim Y., Klein N., Peltier C., Senders S., Shepard J., Wu T., Yeh S., Zissman E., Gillard P., Povey M., Abu-Elyazeed R., Henry O., and Huang L., 2019, A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration, Human Vaccines & Immunotherapeutics, 15: 786-799. https://doi.org/10.1080/21645515.2018.1554971
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==